Press Release Jan 07 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
The award was presented by Sri M. Damodaran, former Chairman of SEBI, and the selection was based on nominations from various industry stakeholders. The jury evaluated companies based on criteria including statutory compliance, board composition, and shareholder communication.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- Press Release Jan 01 2022
- NATCO Pharma receives approval for Molnupiravir Capsules 200 mg for the treatment of Covid-19 in India
- Press Release Dec 28 2021
- Press Release Nov 18 2021
- Natco Pharma launches Everolimus tablets 10 mg in US market
Later from NATCO Pharma
- Press Release Jan 20 2022
- NATCO announces License Agreement with the Medicines Patent Pool
- Press Release Mar 07 2022
- NATCO Announces Launch of the First Generic Version of Revlimid (Lenalidomide capsules), in the U.S. market
- NATCO records INR 2043.8 Crore consolidated revenue and INR 170.0 Crore of profit, after tax, for the year ended March 31' 2022
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma